Want to see CRNX full AI Analyst Report?
CRNX Stock Chart & Stats
$41.00
-$0.61(-1.22%)
At close: 4:00 PM EST
$41.00
-$0.61(-1.22%)
Day’s Range― - ―
52-Week Range$25.83 - $57.99
Previous CloseN/A
Volume214.21K
Average Volume (3M)1.21M
Market Cap
$3.95B
Enterprise Value$3.70B
Total Cash (Recent Filing)$1.29B
Total Debt (Recent Filing)$47.85M
Price to Earnings (P/E)―
Beta1.44
Next Earnings
Aug 04, 2026EPS Estimate
-1.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.14
Shares Outstanding105,440,210
10 Day Avg. Volume1,056,071
30 Day Avg. Volume1,208,364
Financial Highlights & Ratios
PEG Ratio-0.28
Price to Book (P/B)4.41
Price to Sales (P/S)568.91
P/FCF Ratio-11.41
Enterprise Value/Market Cap0.94
Enterprise Value/Revenue204.94
Enterprise Value/Gross Profit207.23
Enterprise Value/Ebitda-7.53
Forecast
1Y Price Target
$88.90Price Target Upside116.83% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-4.8
Revenue Forecast (FY)$68.56M
Bulls Say, Bears Say
Bulls Say
Strong Cash Runway & Balance SheetA cash balance of ~$1.3B and an explicitly stated runway into 2030 provide durable financial flexibility to fund commercialization, multiple pivotal readouts and R&D without near-term dependence on dilutive financings, materially lowering execution risk over the next 2–4 years.
Early Commercial TractionInitial product sales and consistent new patient form adds signal real, repeatable demand rather than one-off milestones. Early revenue plus patient flows suggest the commercial model and distribution channels are functioning and can compound over time as coverage and prescriber adoption expand.
Robust Clinical & Scientific MomentumMultiple ongoing pivotal and supportive trials diversify development risk across programs and indications, increasing the probability of durable value creation from several assets, sustaining scientific credibility with payers and prescribers and supporting longer-term revenue optionality.
Bears Say
High Cash BurnSustained negative operating and free cash flow of several hundred million annually will steadily deplete resources absent rapid commercial scale or additional financing; this raises execution risk, potential future dilution and constrains discretionary investments even with current runway.
Large Net Losses & Expanding Operating LossesPersistently large net losses and widening operating deficits indicate current revenue growth does not yet offset R&D and SG&A scale-up. Over time this dynamic pressures returns on equity and requires continued capital markets access or partnerships to sustain development and commercialization plans.
Commercial Execution & Reimbursement UncertaintyLack of disclosed conversion metrics, an unresolved ~30% reimbursement gap and appointment-driven capacity limits create structural uncertainty in the commercial ramp. These factors can slow predictable revenue scaling and make forecasting uptake, payer conversion timing and breakeven horizons more uncertain.
Crinetics Pharmaceuticals News
CRNX FAQ
What was Crinetics Pharma’s price range in the past 12 months?
Crinetics Pharma lowest stock price was $25.83 and its highest was $57.99 in the past 12 months.
What is Crinetics Pharma’s market cap?
Crinetics Pharma’s market cap is $3.95B.
When is Crinetics Pharma’s upcoming earnings report date?
Crinetics Pharma’s upcoming earnings report date is Aug 04, 2026 which is in 34 days.
How were Crinetics Pharma’s earnings last quarter?
Crinetics Pharma released its earnings results on May 07, 2026. The company reported -$1.23 earnings per share for the quarter, missing the consensus estimate of -$1.221 by -$0.009.
Is Crinetics Pharma overvalued?
According to Wall Street analysts Crinetics Pharma’s price is currently Undervalued.
Does Crinetics Pharma pay dividends?
Crinetics Pharma does not currently pay dividends.
What is Crinetics Pharma’s EPS estimate?
Crinetics Pharma’s EPS estimate is -1.22.
How many shares outstanding does Crinetics Pharma have?
Crinetics Pharma has 105,440,210 shares outstanding.
What happened to Crinetics Pharma’s price movement after its last earnings report?
Crinetics Pharma reported an EPS of -$1.23 in its last earnings report, missing expectations of -$1.221. Following the earnings report the stock price went down -13.819%.
Which hedge fund is a major shareholder of Crinetics Pharma?
Currently, no hedge funds are holding shares in CRNX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Crinetics Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$88.90 (116.83% Upside)
$88.90 (116.83% Upside)
Blogger Sentiment
Bullish
CRNX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 2.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 0.9%
Last 30 Days ▲ 3.1%
Last 30 Days ▲ 3.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
23.29%
12-Months-Change
Fundamentals
Return on Equity
-43.96%
Trailing 12-Months
Asset Growth
2.94%
Trailing 12-Months
Company Description
Crinetics Pharma
Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical enterprise, dedicated to the identification, advancement, and market introduction of therapeutic solutions for infrequent endocrine conditions and related tumors. Their flagship drug candidate, Paltusotine, is an orally administered, selective, non-peptide somatostatin receptor type 2 agonist. This compound has concluded its Phase III clinical trials for the treatment of acromegaly, and has also completed Phase II trials targeting carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). Furthermore, the company's pipeline includes CRN04777, an oral selective non-peptide somatostatin type 5 receptor agonist, which is currently undergoing Phase I clinical trials for congenital hyperinsulinism. Another investigational drug, CRN04894, an oral adrenocorticotrophic hormone antagonist, is in Phase I clinical trials for Cushing's disease and congenital adrenal hyperplasia. Crinetics Pharmaceuticals, Inc. was founded in 2008 and maintains its headquarters in San Diego, California.
CRNX Company Deck
CRNX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated a strong early commercial launch for Palsonify with meaningful patient additions, encouraging reimbursement progress (≈70% reimbursed, >60% coverage), expanding prescriber footprint and robust pipeline advancement, all supported by a strong balance sheet. Offsetting these positives are elevated and rising R&D and operating expenses, limited disclosure of certain commercial conversion metrics, a remaining reimbursement gap (~30% of patients), appointment‑driven adoption constraints, and no firm timelines provided for several key pivotal readouts or international revenue. On balance, the positives around launch momentum, payer traction, prescriber growth and cash runway outweigh the operational and disclosure limitations.View all CRNX earnings summariesCRNX Stock 12 Month Forecast
Average Price Target
$88.90
▲(116.83% Upside)
Technical Analysis
Ownership Overview
1.92% Insiders
38.41% Mutual Funds
42.87% Other Institutional Investors
1.54% Public Companies and
Individual Investors